BNP PARIBAS FINANCIAL MARKETS - INFINITY PHARMACEUTICALS INC ownership

INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 101 filers reported holding INFINITY PHARMACEUTICALS INC in Q1 2014. The put-call ratio across all filers is 1.89 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of INFINITY PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$1,543
+31.7%
7,3280.0%0.00%
Q1 2023$1,172
-75.1%
7,328
-13.7%
0.00%
Q4 2022$4,714
-99.9%
8,494
+10.2%
0.00%
Q3 2022$9,169,000
-16.1%
7,705
-55.4%
0.00%
Q2 2022$10,934,000
+22.0%
17,292
+120.0%
0.00%
Q1 2022$8,962,000
-92.2%
7,861
-84.5%
0.00%
Q4 2021$114,250,000
+109.5%
50,778
+218.4%
0.00%
Q3 2021$54,539,000
+441.1%
15,947
+373.1%
0.00%
Q2 2021$10,079,000
+503850.0%
3,371
+337000.0%
0.00%
Q4 2020$2,000
+100.0%
10.0%0.00%
Q3 2020$1,0000.0%10.0%0.00%
Q2 2020$1,0000.0%10.0%0.00%
Q1 2020$1,0000.0%10.0%0.00%
Q4 2019$1,000
-99.7%
1
-99.7%
0.00%
Q3 2019$301,000
-42.8%
2920.0%0.00%
Q2 2019$526,000
-4.2%
2920.0%0.00%
Q1 2019$549,000
+59.1%
2920.0%0.00%
Q4 2018$345,000
-56.4%
2920.0%0.00%
Q3 2018$791,000
+41.8%
2920.0%0.00%
Q2 2018$558,000
-9.0%
2920.0%0.00%
Q1 2018$613,000
+3.4%
2920.0%0.00%
Q4 2017$593,000
-74.6%
292
-83.4%
0.00%
Q3 2017$2,334,000
-63.3%
1,755
-56.7%
0.00%
Q2 2017$6,368,000
+8869.0%
4,056
+18336.4%
0.00%
Q1 2017$71,000
+22.4%
22
-48.8%
0.00%
Q4 2016$58,000
-98.9%
43
-98.8%
0.00%
Q3 2016$5,413,000
+138.0%
3,470
+102.9%
0.00%
Q2 2016$2,274,000
-97.4%
1,710
-84.7%
0.00%
Q4 2015$88,014,000
+1.2%
11,212
+9.0%
0.00%
Q3 2015$86,951,000
+94.6%
10,290
+152.2%
0.00%
Q2 2015$44,676,000
+179.1%
4,080
+256.3%
0.00%
Q1 2015$16,007,000
-58.5%
1,145
-60.1%
0.00%
Q3 2014$38,529,000
+1090.6%
2,871
+1030.3%
0.00%
Q2 2014$3,236,000
+461.8%
254
+330.5%
0.00%
Q1 2014$576,000
-93.3%
59
-90.5%
0.00%
Q4 2013$8,576,000
-96.2%
621
-95.2%
0.00%
Q3 2013$227,601,000
-20.7%
13,058
-26.3%
0.00%
Q2 2013$287,000,00017,7270.00%
Other shareholders
INFINITY PHARMACEUTICALS INC shareholders Q1 2014
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,100,000$14,762,0006.34%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,882,805$52,107,0001.90%
Cheyne Capital Management (UK) LLP 326,821$4,388,0001.56%
BB BIOTECH AG 2,320,737$31,144,0001.27%
Broadfin Capital, LLC 854,384$11,466,0001.20%
HealthCor Management, L.P. 1,162,200$15,597,0000.80%
Orbimed Advisors 4,736,900$63,569,0000.66%
Rhenman & Partners Asset Management AB 148,000$1,986,0000.58%
SOUND ENERGY PARTNERS, INC. 51,000$684,0000.53%
Rock Springs Capital Management LP 210,000$2,818,0000.44%
View complete list of INFINITY PHARMACEUTICALS INC shareholders